» Articles » PMID: 30110274

Correlation Between Apolipoprotein M and Inflammatory Factors in Obese Patients

Overview
Journal Med Sci Monit
Date 2018 Aug 16
PMID 30110274
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

BACKGROUND The aim of this study was to observe apolipoprotein M (ApoM) level in obese patients and to explore its correlation with inflammatory factors. MATERIAL AND METHODS A total number of 96 participants were recruited and divided into 2 groups: the control group (or healthy group) whose participants had normal body weight (n=58), and the obese group with all its participants diagnosed with obesity (n=38). Data on blood pressure, body weight, height, body mass index, diastolic function of brachial artery endothelium, fasting venous blood glucose, blood lipids, plasmatic ApoM, interleukin-6 (IL-6), C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), fasting insulin, and adiponectin levels were collected for both groups. RESULTS In the obese group, the levels of plasmatic ApoM, high-density lipoprotein cholesterol (HDL-C), and plasmatic adiponectin were significantly (p<0.05) decreased compared to the control group, and the levels of IL-6, TNF-α, CRP, and fasting insulin were significantly increased (p<0.05) compared to the control group. For the obese group, plasmatic ApoM level was positively correlated with HDL-C level and negatively correlated with levels of IL-6, TNF-α, CRP, insulin, and insulin resistance index. However, no significant correlations were revealed between plasmatic ApoM and the diastolic function of brachial artery endothelium, adiponectin level, blood pressure, and blood glucose level. CONCLUSIONS Obese patients showed significantly lower plasmatic ApoM levels than people with normal body weight, and ApoM level showed a strong correlation with CRP, TNF-α, and IL-6 levels, which indicated that ApoM might be regulated by these inflammatory factors.

Citing Articles

Effects of dietary interventions and intermittent fasting on HDL function in obese individuals with T2DM: a randomized controlled trial.

Pammer A, Obermayer A, Stadler J, Pferschy P, Tripolt N, Habisch H Cardiovasc Diabetol. 2024; 23(1):339.

PMID: 39267053 PMC: 11395628. DOI: 10.1186/s12933-024-02426-5.


Identification of circulating apolipoprotein M as a new determinant of insulin sensitivity and relationship with adiponectin.

Frances L, Croyal M, Ruidavets J, Maraninchi M, Combes G, Raffin J Int J Obes (Lond). 2024; 48(7):973-980.

PMID: 38491190 PMC: 11216985. DOI: 10.1038/s41366-024-01510-w.


Could Tumor Necrosis Factor Serve as a Marker for Cardiovascular Risk Factors and Left Ventricular Hypertrophy in Patients with Early-Onset Coronary Artery Disease?.

Bialecka M, Dziedziejko V, Safranow K, Krzystolik A, Marcinowska Z, Chlubek D Diagnostics (Basel). 2024; 14(4).

PMID: 38396488 PMC: 10887573. DOI: 10.3390/diagnostics14040449.


High density lipoprotein-associated proteins in non-obese women with and without polycystic ovary syndrome.

Butler A, Moin A, Reiner Z, Sathyapalan T, Jamialahmadi T, Sahebkar A Front Endocrinol (Lausanne). 2023; 14:1117761.

PMID: 37181037 PMC: 10171110. DOI: 10.3389/fendo.2023.1117761.


An association between adropin hormone and total testosterone in obese men: a case-control study.

Muhammed A, Eid R, Mohammed W, Abdel-Fadeil M BMC Endocr Disord. 2022; 22(1):192.

PMID: 35897011 PMC: 9327160. DOI: 10.1186/s12902-022-01102-7.


References
1.
Celermajer D, Sorensen K, Gooch V, Spiegelhalter D, Miller O, Sullivan I . Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992; 340(8828):1111-5. DOI: 10.1016/0140-6736(92)93147-f. View

2.
Zhang Y, Huang L, Yang Q, Liu Y, Zhou X . Correlation analysis between ApoM gene-promoter polymorphisms and coronary heart disease. Cardiovasc J Afr. 2016; 27(4):228-237. PMC: 5340899. DOI: 10.5830/CVJA-2016-001. View

3.
Wolfrum C, Howell J, Ndungo E, Stoffel M . Foxa2 activity increases plasma high density lipoprotein levels by regulating apolipoprotein M. J Biol Chem. 2008; 283(24):16940-9. DOI: 10.1074/jbc.M801930200. View

4.
Senn J, Klover P, Nowak I, Zimmers T, Koniaris L, Furlanetto R . Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem. 2003; 278(16):13740-6. DOI: 10.1074/jbc.M210689200. View

5.
Kumaraswamy S, Linder A, Akesson P, Dahlback B . Decreased plasma concentrations of apolipoprotein M in sepsis and systemic inflammatory response syndromes. Crit Care. 2012; 16(2):R60. PMC: 3681389. DOI: 10.1186/cc11305. View